Survodutide — EU research guide.
Survodutide (BI 456906) is a dual GLP-1 receptor and glucagon receptor agonist developed by Boehringer Ingelheim / Zealand Pharma, studied for obesity and MASH (metabolic-associated steatohepatitis).
What is Survodutide?
Survodutide activates both GLP-1R (promoting satiety and insulin secretion) and GCGR (increasing energy expenditure and hepatic fat metabolism). The glucagon component distinguishes it from semaglutide and gives it a stronger liver-directed metabolic effect, making it of particular interest in MASH research.
What does the research show?
Phase 2 results showed ~19% body weight reduction at 46 weeks. In MASH patients, significant liver fat reduction and histological improvement were observed. Phase 3 trials are ongoing. The GCGR activation carries theoretical risk of hyperglycaemia in non-obese subjects — an active research area.
EU legal status
Not EMA or FDA approved. Investigational compound available for laboratory research purposes only.
Molecular information
Pharmacokinetics
Survodutide across EU suppliers
COA-verified EU vendors · Updated monthly